Results 31 to 40 of about 24,414 (214)
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors [PDF]
Clinical Research in Cardiology Supplements, 2019 Lipoprotein(a) (Lp(a)) is an internationally accepted independent atherogenic risk factor. Details about its synthesis, many aspects of composition and clearance from the bloodstream are still unknown. LDL receptor (LDLR) (and probably other receptors) play a role in the elimination of Lp(a) particles.
Julius, U +4 more
openaire +2 more sources
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Journal of Lipid Research, 2007 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however, remain to be defined.
Yue-Wei Qian +16 more
doaj +1 more source
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Медицинский совет, 2021 Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva +2 more
doaj +1 more source
Diabetes Care, 2021 OBJECTIVE Dyslipidemia observed in type 2 diabetes (T2D) is atherogenic. Important features of diabetic dyslipidemia are increased levels of triglyceride-rich lipoproteins and small dense LDL particles, which all have apolipoprotein B100 (apoB100) as a ...
B. Vergès +8 more
semanticscholar +1 more source
Liver international (Print), 2021 Proprotein convertase subtilisin/kexin type 9 (PCSK9) controls blood cholesterol levels by fostering the LDL receptor (LDLR) degradation in hepatocytes.
Dafne Jacome Sanz +7 more
semanticscholar +1 more source
P8 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION
Artery Research, 2017 Purpose/Background/Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are modestly but significantly associated with increased risk of total cardiovascular events.
Losif Koutagiar +7 more
doaj +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview [PDF]
The American Journal of Medicine, 2017 Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density
Zachary R, Noel, Craig J, Beavers
openaire +2 more sources
Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
Journal of Cardiovascular Pharmacology and Therapeutics, 2014 Proprotein convertase subtilisin/kexin 9 (PCSK9) is part of the proteinase K subfamily of subtilases and plays a key role in lipid metabolism. It increases degradation of the low-density lipoprotein receptor (LDL-R), modulates cholesterol metabolism and transport, and contributes to the production of apolipoprotein B (apoB) in intestinal cells ...
Simona, Dragan +2 more
openaire +2 more sources
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Journal of Lipid Research, 2008 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained attention as a key regulator of serum low density lipoprotein cholesterol (LDL-C) levels. This novel protease causes the degradation of hepatic low density lipoprotein receptors. In humans,
Holly E. Careskey +5 more
doaj +1 more source
Stroke, 2020 Supplemental Digital Content is available in the text. Background and Purpose— The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5–1.2) mmol/L and ...
R. Giugliano +11 more
semanticscholar +1 more source